Ras

KRAS-IN-47 (Example 28) is a KRAS inhibitor with an IC50 value of less than 50 nM for KRAS G12V. It is applicable in cancer research.

RAS GTPase inhibitor 1 Free Base is a highly potent RAS GTPase inhibitor with antitumor activity.

Sotorasib-D7 is a deuterium-labeled version of Sotorasib. Sotorasib (T8684) (AMG-510) is a potent, orally bioavailable, selective covalent inhibitor of KRAS G12C. It locks KRAS G12C in the inactive GDP-bound state and causes regression of locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation.

A unique collection of xnum cancer cell differentiation inducing compounds for high throughput and high content screening;

ADT-007 is a pan-RAS inhibitor with potent anticancer activity.

AM-001 is a non-competitive Epac1 inhibitor that blocks Rap1 activation and is used in heart disease research.

6-Thio-GTP (tetrasodium) is an inhibitor of Vav1-Rac. It can suppress TCR-induced T cell proliferation and CD28-mediated T cell survival. In a murine model of allogeneic heart transplantation, 6-Thio-GTP (tetrasodium) demonstrates immunosuppressive effects, which can prolong the survival time of heart transplants.

TAT-PAK18 R192A is an inactive Tat-Pak peptide. It does not influence Rac1 translocation triggered by any tested proteins.

KRAS-IN-43 (Compound 9) is a broad-spectrum KRAS inhibitor with IC50 values of 0.15 μM for KRASG12V, 0.14 μM for KRASG12C, and 0.47 μM for wild-type KRAS. It disrupts the interaction between KRAS and cRAF and suppresses ERK phosphorylation. KRAS-IN-43 shows potential for research in KRAS mutation-associated cancers, including pancreatic, colorectal, and lung cancers.

(RS)-G12Di-1 is a selective covalent inhibitor of K-Ras-G12D.

Peptide (45-60) blocks Rac1 binding with TrioN, GEF-H1, Tiam1 GEFs.

KRASG12C IN-14 (compound 15), a potent inhibitor specifically designed for the KRAS G12C mutation, exhibits impressive efficacy in impeding CYPA-dependent KRAS-BRAF interaction and ERK phosphorylation in NCI-H358 cells, both with an IC 50 of 0.002 μM.

ASP6918 is a potent, orally active KRAS G12C inhibitor with an IC50 of 0.028 µM. It inhibits cell growth and demonstrates antitumor activity.

KRAS inhibitor-42 (compound 8) is an effective USP7 inhibitor that exhibits high affinity for GDP-bound KRASG12D, with a Ki value of 2.7 μM.

Anticanceragent 207 (compound 10b) is an effective anticancer agent. It binds to NRAS rG4 with a KD value of 2.31 µM. It exhibits cytotoxicity and reduces NRAS protein expression, demonstrating antitumor activity.

Rac1 Inhibitor F56, control peptide TFA, is a peptide containing Rac1 residues 45-60. It features a mutation from Trp56 to Phe56. This inhibitor does not affect the interaction between Rac1 and guanine nucleotide exchange factors (GEFs).

GGDPS-IN-1 (Compound 37) is an inhibitor of geranylgeranyl diphosphate synthase (GGDPS) with an IC50 of 49.4 nM, disrupting protein geranylgeranylation in myeloma cells.

KRpep-2d, a potent inhibitor of K-Ras, effectively suppresses the proliferation of cancer cells driven by K-Ras.

Bioavailable pan-RAS(ON) inhibitor is a class of pan-RAS ternary complex inhibitors targeting the RAS GTP-bound active state (RAS(ON)), which can form ternary complexes with RAS and cyclophilin A through non-covalent binding, thereby blocking the interaction of RAS with downstream effector proteins and related signaling. Related compounds of Bioavailable pan-RAS(ON) inhibitor can be used for research on RAS signaling pathway regulation, pharmacodynamic evaluation, RAS-driven tumors and resistance mechanisms, and combination therapy strategies.

Pan-KRAS-IN-10 (Compound 58) acts as an inhibitor of the human tumor mutant gene KRAS. It suppresses the proliferation of KRAS mutant cells, specifically AsPC-1 (G12D mutant) and SW480 (G12V mutant), with IC50 values of 0.7 and 0.24 nM, respectively.